{"id":"523e3189-3d87-5b97-82b9-7c7459a87067","stable_key":"0a5134ca-a214-59b8-8017-f89b299ace92:gemfibrozil-raises-cerivastatin-exposure","predicate":"increases","statement":"Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"61511908-23ca-544c-8faf-7b4332ba185b","mechanism_event_label":"Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.","subject":{"id":"be172818-3b91-5a27-8657-a620397442da","slug":"gemfibrozil","display_name":"Gemfibrozil","entity_type_key":"drug"},"object":{"id":"45564888-eb93-5ac1-956f-d362732fc9cc","slug":"cerivastatin-plasma-exposure","display_name":"Plasma cerivastatin exposure","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"61511908-23ca-544c-8faf-7b4332ba185b","stable_key":"0a5134ca-a214-59b8-8017-f89b299ace92:gemfibrozil-raises-cerivastatin-exposure-event","event_type":"observed_relationship","label":"Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.","description":"Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"be172818-3b91-5a27-8657-a620397442da","slug":"gemfibrozil","display_name":"Gemfibrozil","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"45564888-eb93-5ac1-956f-d362732fc9cc","slug":"cerivastatin-plasma-exposure","display_name":"Plasma cerivastatin exposure","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"ade21be6-666e-59a9-8b89-06996f86551f","slug":"cerivastatin","display_name":"Cerivastatin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"3 days of gemfibrozil, 24 hours of sampling","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"10 healthy volunteers, randomised double-blind crossover","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Gemfibrozil 600 mg twice daily for 3 days, then a single 0.3 mg cerivastatin dose","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Metabolite M-23 exposure fell to 22 percent of control while the parent and other metabolites rose, so the interaction shifts the metabolic route rather than simply slowing clearance. Between-subject variation was wide.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"10 healthy volunteers, randomised double-blind crossover","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma cerivastatin, cerivastatin lactone and its metabolites","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"7728ea6b-1ccc-5df3-b56a-6456dfd27430","evidence_kind":"source_excerpt","locator":"Lines 46-55","start_line":46,"end_line":55,"excerpt":"## gemfibrozil-raises-cerivastatin-exposure\nGemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.\nModel/species: 10 healthy volunteers, randomised double-blind crossover\nTissue/system: Plasma cerivastatin, cerivastatin lactone and its metabolites\nExposure: Gemfibrozil 600 mg twice daily for 3 days, then a single 0.3 mg cerivastatin dose\nRoute: Oral\nDuration: 3 days of gemfibrozil, 24 hours of sampling\nLimits: Metabolite M-23 exposure fell to 22 percent of control while the parent and other metabolites rose, so the interaction shifts the metabolic route rather than simply slowing clearance. Between-subject variation was wide.\nPrimary reference: Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"6e42a53a-5f31-5a81-87ba-a3edc49aface","stable_key":"import-0a5134ca-a214-59b8-8017-f89b299ace92","title":"Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text.","file_path":"","sha256":"33f81004d0b40ff01b3cc13113ba2991833a171a7a535fdf1c2d3c015f9f7b1c","revision_id":"3ccfa03e-b7ed-5569-9e22-af3e5de65955","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}